Financed projects under way
CardioCAPS
Increasing drug safety by implementing Celon Pharma S.A. in its own production innovative oral forms of three medicinal products used in the pharmacotherapy of cardiovascular diseases
FAIND 2.0
FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases
Development of Innovative Therapeutic Solutions Using RNA Technology
Develop clinical candidates based on mRNA technology in 3 therapeutic areas (oncological, metabolic – AATD deficiency and viral – SARS-CoV2), as well as to develop and expand the competence of Celon Pharma S.A. in the area of pharmaceutical production in the area of mRNA
CELONKO
CELONKO – “Development of modern biomarkers and development of an innovative FGFR kinases inhibitor”
Finished funded projects
NoteSzHD
NoteSzHD – “New therapy in psychotic disorders and Huntington’s disease with special focus on cognitive deficits” .